Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 15, 2026, 8:22 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 793–816 of 5,558 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Degenerative Conditions, Neurologic Clear all
Recruiting Phase 4 Interventional

Cardiac Magnetic Resonance and Echocardiography Study With Acoramidis

NCT07695701
View directory record Official record
Conditions
Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM), Amyloidosis, Amyloid Cardiomyopathy, Transthyretin Amyloidosis
Interventions
Acoramidis (AG10) oral tablet
Drug
Lead sponsor
Eidos Therapeutics, a BridgeBio company
Industry
Eligibility
18 Years to 80 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jul 29, 2026 · Synced Oct 15, 2026, 8:22 PM EDT
Completed No phase listed Observational

Opicapone Treatment Initiation Open-Label Study

NCT04787965
View directory record Official record
Conditions
Parkinson Disease
Interventions
Opicapone
Drug
Lead sponsor
Neurocrine Biosciences
Industry
Eligibility
18 Years and older
Enrollment
239 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
6
States / cities
Los Gatos, California • Memphis, Tennessee • Christiansburg, Virginia + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 28, 2022 · Synced Oct 15, 2026, 8:22 PM EDT
Completed Phase 1 Interventional Results available

An Exploratory Study Investigating Safety, Tolerability and Pharmacokinetics of Ascending Doses of Lu AE04621 in Parkinson Disease Patients

NCT02649608
View directory record Official record
Conditions
Parkinson Disease
Interventions
0.04 mg Lu AE04621, 0.08 mg Lu AE04621, 0.2 mg Lu AE04621, 0.4 mg Lu AE04621, 0.6 mg Lu AE04621, 0.8 mg Lu AE04621, 1.0 mg Lu AE04621, 1.2 mg Lu AE04621
Drug
Lead sponsor
H. Lundbeck A/S
Industry
Eligibility
45 Years to 75 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
4
States / cities
Hallandale, Florida • Orlando, Florida • Chicago, Illinois + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 24, 2021 · Synced Oct 15, 2026, 8:22 PM EDT
Completed Phase 4 Interventional Results available

Mirabegron in Parkinson Disease and Impaired Cognition

NCT02536976
View directory record Official record
Conditions
Parkinson Disease, Overactive Bladder, Impaired Cognition
Interventions
mirabegron, Placebo
Drug
Lead sponsor
HealthPartners Institute
Other
Eligibility
25 Years to 80 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Golden Valley, Minnesota
Source: ClinicalTrials.gov public record
Updated May 8, 2019 · Synced Oct 15, 2026, 8:22 PM EDT
Completed Phase 2 Interventional Results available

A Study to Explore the Safety And Tolerability of Doses of E2007 Up to a Maximum of 8 mg In Patients With Parkinson's Disease Who Experience End-of-Dose Wearing Off Motor Fluctuations

NCT00165789
View directory record Official record
Conditions
Parkinson's Disease
Interventions
E2007
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
10
States / cities
Little Rock, Arkansas • Oxnard, California • New Haven, Connecticut + 7 more
Source: ClinicalTrials.gov public record
Updated Jun 2, 2015 · Synced Oct 15, 2026, 8:22 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Improved Diagnosis of Alzheimer's Disease Using Magnetoencephalography (MEG)

NCT00973518
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Not listed
Lead sponsor
Orasi Medical, Inc.
Industry
Eligibility
50 Years to 90 Years
Enrollment
160 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
2
States / cities
Chicago, Illinois • Elk Grove Village, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 13, 2010 · Synced Oct 15, 2026, 8:22 PM EDT
Completed Phase 3 Interventional Results available

Open Label Extension (OLE) Study of the Safety and Clinical Utility of IPX203 in Parkinson's Disease (PD) Participants With Motor Fluctuations

NCT03877510
View directory record Official record
Conditions
Parkinson Disease
Interventions
IPX203
Drug
Lead sponsor
Impax Laboratories, LLC
Industry
Eligibility
40 Years and older
Enrollment
419 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
50
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Los Angeles, California + 40 more
Source: ClinicalTrials.gov public record
Updated Jul 13, 2023 · Synced Oct 15, 2026, 8:22 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluation of [123I] AV51 and SPECT as a Marker of Beta-amyloid Protein Deposition in Subjects With Alzheimer Disease in Comparison to Healthy Subjects

NCT00556660
View directory record Official record
Conditions
Alzheimer Disease
Interventions
[123I] AV-151
Drug
Lead sponsor
Institute for Neurodegenerative Disorders
Other
Eligibility
50 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
2
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Mar 14, 2019 · Synced Oct 15, 2026, 8:22 PM EDT
Completed No phase listed Observational

Equality in Caregiving: Facilitating Caregiver Mastery Among LGBT Caregivers of PLWD

NCT04394260
View directory record Official record
Conditions
Dementia, Caregiver Burnout
Interventions
Savvy Caregiver Program via Remote Learning, Focus group
Behavioral
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Mar 10, 2023 · Synced Oct 15, 2026, 8:22 PM EDT
Completed Phase 4 Interventional Results available

RECHARGE Sub-Study to the Implantable Systems Performance Registry (ISPR)

NCT00998660
View directory record Official record
Conditions
Parkinson's Disease, Essential Tremor, Dystonia
Interventions
Activa RC
Device
Lead sponsor
MedtronicNeuro
Industry
Eligibility
7 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
5
States / cities
Washington D.C., District of Columbia • Cincinnati, Ohio • Nashville, Tennessee + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 6, 2015 · Synced Oct 15, 2026, 8:22 PM EDT
Completed No phase listed Observational

Developmental Phenomenology of Obsessive Compulsive Disorder and Tourette Syndrome in Children and Adolescents

NCT00004324
View directory record Official record
Conditions
Tourette Syndrome, Obsessive Compulsive Disorder
Interventions
Not listed
Lead sponsor
National Center for Research Resources (NCRR)
NIH
Eligibility
5 Years to 17 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1989
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 15, 2026, 8:22 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Supporting Our Caregivers In ADRD Learning (SOCIAL)

NCT06276023
View directory record Official record
Conditions
Alzheimer's Disease and Related Dementias, Quality of Life, Caregiver Stress
Interventions
Mindful and Self-Compassionate Care Program (MASC), Health Education Program (HEP)
Behavioral
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
82 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Oct 15, 2026, 8:22 PM EDT
Completed Phase 2 Interventional Results available

Citalopram to Enhance Cognition in HD

NCT00271596
View directory record Official record
Conditions
Huntington Disease, Chorea, Executive Dysfunction
Interventions
20mg daily citalopram, Placebo
Drug
Lead sponsor
University of Iowa
Other
Eligibility
18 Years to 75 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
3
States / cities
Scottsdale, Arizona • Iowa City, Iowa • Rochester, New York
Source: ClinicalTrials.gov public record
Updated Mar 13, 2013 · Synced Oct 15, 2026, 8:22 PM EDT
Not listed No phase listed Observational

Prospective Single-Timepoint Huntington's Disease Biospecimen Collection Study

NCT05773196
View directory record Official record
Conditions
Huntington Disease, Huntington's Dementia, Huntington Disease, Late Onset, Huntington; Dementia (Etiology)
Interventions
Biospecimen Collection
Other
Lead sponsor
Sanguine Biosciences
Industry
Eligibility
25 Years to 65 Years
Enrollment
5 participants
Timeline
2023 – 2025
U.S. locations
1
States / cities
Woburn, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 18, 2024 · Synced Oct 15, 2026, 8:22 PM EDT
Completed Phase 2Phase 3 Interventional

AMX0035 and Progressive Supranuclear Palsy

NCT06122662
View directory record Official record
Conditions
Progressive Supranuclear Palsy, PSP, Neurodegenerative Diseases, Atypical Parkinsonism
Interventions
AMX0035, Placebo
Drug · Other
Lead sponsor
Amylyx Pharmaceuticals Inc.
Industry
Eligibility
40 Years to 80 Years
Enrollment
139 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
35
States / cities
Scottsdale, Arizona • Little Rock, Arkansas • Fountain Valley, California + 31 more
Source: ClinicalTrials.gov public record
Updated Apr 30, 2026 · Synced Oct 15, 2026, 8:22 PM EDT
Completed Phase 2 Interventional

Efficacy and Safety of 26-Week Treatment of AR1001 in Patients With Mild to Moderate Alzheimer's Disease

NCT03625622
View directory record Official record
Conditions
Mild to Moderate Alzheimer's Disease
Interventions
AR1001, Placebo
Drug
Lead sponsor
AriBio Co., Ltd.
Industry
Eligibility
55 Years to 80 Years
Enrollment
210 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
21
States / cities
Banning, California • Sacramento, California • Santa Ana, California + 18 more
Source: ClinicalTrials.gov public record
Updated Jul 21, 2021 · Synced Oct 15, 2026, 8:22 PM EDT
Enrolling by invitation Not applicable Interventional

TMS Pilot in Early AD II

NCT06817902
View directory record Official record
Conditions
Alzheimer Disease
Interventions
Intermittent theta burst stimulation active coil, Sham coil
Device
Lead sponsor
HealthPartners Institute
Other
Eligibility
40 Years to 90 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 7, 2026 · Synced Oct 15, 2026, 8:22 PM EDT
Active, not recruiting Phase 1 Interventional

Feasibility and Safety of autoloGous UncondItioneD pEripheral Nerve Tissue Delivery to the Substantia Nigra (GUIDE)

NCT05377281
View directory record Official record
Conditions
Parkinson's Disease
Interventions
Peripheral Nerve Tissue Implantation
Procedure
Lead sponsor
Craig van Horne, MD, PhD
Other
Eligibility
40 Years to 75 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Aug 31, 2026 · Synced Oct 15, 2026, 8:22 PM EDT
Completed Phase 1Phase 2 Interventional Results available

A Clinical Trial of Dantrolene Sodium in Pediatric and Adult Patients With Wolfram Syndrome

NCT02829268
View directory record Official record
Conditions
Wolfram Syndrome, Diabetes Mellitus, Optic Nerve Atrophy, Ataxia
Interventions
dantrolene sodium
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
5 Years to 60 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Mar 13, 2024 · Synced Oct 15, 2026, 8:22 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Neurogenetic Pharmaceuticals (NGP) 555 in Healthy Young Volunteers (Single-ascending Dose)

NCT02534480
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
NGP 555
Drug
Lead sponsor
NeuroGenetic Pharmaceuticals Inc
Industry
Eligibility
18 Years to 55 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Cypress, California
Source: ClinicalTrials.gov public record
Updated Jan 13, 2016 · Synced Oct 15, 2026, 8:22 PM EDT
Recruiting No phase listed Observational

Cognitive Assessment Tools for Huntington's Disease.

NCT06546488
View directory record Official record
Conditions
Huntington Disease
Interventions
Assessments
Behavioral
Lead sponsor
Ohio State University
Other
Eligibility
30 Years to 65 Years
Enrollment
76 participants
Timeline
2025 – 2027
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 2, 2026 · Synced Oct 15, 2026, 8:22 PM EDT
Active, not recruiting Not applicable Interventional

Home Transcranial Direct Current Stimulation (tDCS) to Enhance Functional Recovery

NCT07091396
View directory record Official record
Conditions
Stroke, Neurodegeneration, Brain Tumor
Interventions
Soterix® tDCS - Home treatment, Cognitive-linguistic therapy, Soterix® tDCS - Lab treatment
Device · Behavioral
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Oct 15, 2026, 8:22 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Passport to Brain Wellness in Sedentary Adults

NCT00979446
View directory record Official record
Conditions
Mild Cognitive Impairment, Alzheimer's Disease
Interventions
Guided, Self-directed
Behavioral
Lead sponsor
HealthPartners Institute
Other
Eligibility
60 Years to 80 Years
Enrollment
63 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
Bloomington, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 18, 2009 · Synced Oct 15, 2026, 8:22 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Cardiac-Control Affecting Learning Through Mindfulness (CALM)

NCT06410157
View directory record Official record
Conditions
Age-related Cognitive Decline, Alzheimer Disease
Interventions
Daily practice
Behavioral
Lead sponsor
University of Southern California
Other
Eligibility
50 Years to 70 Years
Enrollment
240 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 13, 2026 · Synced Oct 15, 2026, 8:22 PM EDT